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ABSTRACT
Background: The role of laparoscopy in the management
of early stage endometrial and cervical cancer is continu-
ously validated by many reports throughout the world.
Interestingly, such data are still unavailable in many Eu-
ropean countries, as it is in Greece. In this prospective
study, we report on initial feasibility, safety, and cost
outcomes of laparoscopic management of early stage en-
dometrial and cervical cancer, recently introduced in our
country.
Materials and Methods: This was a prospective pilot
study comprising a case series. Patients referred to a ter-
tiary referral medical center with a recent diagnosis of
endometrial or cervical cancer were evaluated, and those
meeting inclusion criteria were offered laparoscopic sur-
gical staging.
Results: Out of 64 patients evaluated, 17 with early clin-
ical stage endometrial cancer and 8 with early clinical
stage cervical cancer underwent successful laparoscopic
staging. Mean patient age was 61.6 and 39.2 years, mean
BMI was 32.3 and 24.1kg/m
2, mean operative time was
243 and 284 minutes, mean estimated blood loss was
190mL and 270mL, mean lymph node count was 27.2 and
29.1, and mean hospital stay was 2 and 3 days for endo-
metrial and cervical cancer cases, respectively. The overall
costs for the procedures performed were not greater than
their laparotomy counterpart. One intraoperative compli-
cation was managed laparoscopically, and 2 cases oc-
curred of postoperative lymphocyst formation.
Conclusion: To our knowledge, this is the first study of
laparoscopic management of early endometrial and cer-
vical cancer in Greece. Our preliminary data support the
feasibility, safety, and cost effectiveness of laparoscopic
management of early endometrial and cervical cancer in
our country and are in accordance with series reported in
the international literature.
Key Words: Laparoscopy, Radical hysterectomy, Endo-
metrial cancer, Cervical cancer.
INTRODUCTION
Since the first case reports of laparoscopic management of
early endometrial and cervical cancer in the late 80s and
early 90s,1,2 many case-series have demonstrated the fea-
sibility, safety, and advantages of laparoscopic staging of
gynecologic malignancies.3–7 Recent studies have also
shown equivalent long-term survival outcomes of laparo-
scopic staging compared with those of the abdominal
staging procedures.8,9
Although laparoscopic surgery has been routinely per-
formed in our country for benign gynecologic conditions
for nearly 2 decades, its adoption in the management of
gynecologic malignancies is still at a preliminary stage. A
total laparoscopic radical hysterectomy (type III) with
pelvic and paraaortic lymphadenectomy for cervical can-
cer was first described in late 2004, published a year later10
and marked the opening of our pilot study. Thereafter, we
report our preliminary data on the feasibility, safety, and
cost of laparoscopic management of early stage endome-
trial and cervical cancer in Greece. We discuss our expe-
rience, and a review of the literature is provided.
MATERIALS AND METHODS
In November 2004, a database was created at our institu-
tion, commencing a prospective pilot study on the feasi-
bility safety and costs of laparoscopic management of
early endometrial and cervical cancers. Eligible candidates
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SCIENTIFIC PAPERwere offered total laparoscopic radical or total laparo-
scopic extrafascial hysterectomy, as well as systematic
pelvic lymphadenectomy. If high-risk features were peri-
operatively identified, such as grossly involved pelvic
nodes, suspected stage IC or greater endometrial cancer
as well as bulky stage IB1 or greater cervical cancer,
additional paraaortic lymph node dissection was insti-
tuted.
A total of 64 new cases were evaluated. Eligibility criteria
for a laparoscopic approach were defined as Eastern Co-
operative Oncology Group (ECOG) or Zubrod perfor-
mance status 2, primary disease, early stage endometrial
cancer (IA to IIB), and early clinical stage cervical cancer
(IA2 to IIA). Exclusion criteria were poor performance
status, recurrent or suspected advanced stage disease, a
history of incompletely staged prior laparotomy or lapa-
roscopy, or those diagnosed based on a posthysterectomy
pathology report, who had been referred for complete
surgical staging, were also excluded.
After thorough evaluation, 41 patients were deemed op-
erable. The remainder (n23) were excluded due to poor
performance status (n8) or advanced stage disease
(n15). Of the operable patients (n41), 15 (n15) were
excluded due to recent a history of an incompletely staged
procedure (n7), diagnosis provided on a posthysterec-
tomy specimen (n3), or recurrent disease (n5). Those
cases were managed independently. Twenty-six patients
met eligibility criteria for our study. One patient refused
the laparoscopic approach despite eligibility (Figure 1).
All patients with endometrial cancer had a preoperative
dilatation and fractional curettage or hysteroscopy D&C.
Patients with microscopic preclinical cervical cancer had a
cold knife cone biopsy. All patients underwent MRI, ac-
cording to our institution’s protocol, evaluation of the
abdomen and pelvis, and a chest x-ray as part of the
preoperative evaluation. The night before, a mechanical
and antibiotic bowel preparation was administered along
with a prophylactic dose of low-molecular weight heparin
12 hours before the procedure.11 Ureteral stents were
placed in 2 patients who had a history of previous ab-
dominal surgery for diverticular colon disease and endo-
metriosis, respectively.
All cases were managed by the same surgeon and oper-
ating room personnel. All portions of the procedures were
performed entirely laparoscopically.
Lymph nodes were retrieved in a laparoscopic bag and
removed through the suprapubic port in all cases. Preop-
erative clinical stage, operative time, lymph nodes re-
trieved, estimated blood loss, and hospital stay were
recorded. All intraoperative complications and complica-
tions that occurred within the first 30 postoperative days
were also included in the analysis.
RESULTS
From November 2004 until September 2008, 25 patients
met inclusion criteria and were laparoscopically managed,
17 patients with early stage endometrial cancer and 8 with
early stage cervical cancer. A total laparoscopic hysterec-
tomy and bilateral salpingo-oophorectomy (BSO) was
performed for endometrial cancer cases, and a total lapa-
roscopic radical hysterectomy (type II or III) with or with-
out BSO (depending on risk factors or age) was per-
formed in cervical cancer patients. Mean patient age was
61.6 years and 39.2 years and mean BMI was 32.3 kg/m
2
and 24.1 kg/m
2 in endometrial and cervical cancer pa-
tients respectively. Patient characteristics and demograph-
ics are summarized in Table 1.
A complete pelvic lymphadenectomy was carried out in
all endometrial and cervical cancer patients. Of the endo-
metrial cancer patients (n18), 3 had suspected or known
high-risk features and underwent additional paraaortic
lymphadenectomy. The first had a grade 2 endometrioid
endometrial cancer with macroscopic evidence of tumor
invasion of more than one-half of the myometrium upon
inspection of the open specimen on the operating table
(clinical stage IC), the second one was a patient with
Patients Referred, N=64
Operable, N=41 Excluded as Inoperable, 
N=23
Operable, N=41
Meeting Criteria for Study, 
N=26
Excluded, N=15
Eligible Patients, N=26
Total Patients Undergoing 
Laparoscopic Staging, N=25
Patients Refusing 
Laparoscopic Approach, 
N=1
Figure 1. Patient selection diagram.
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roscopic evidence of tumor, extending below the isthmus
into the cervix (clinical stage IIA), and the third had stage
IA clear cell endometrial carcinoma. Finally, there was one
case of poorly differentiated stage IIA barrel-shaped squa-
mous cervical cancer, in which an extended paraaortic
lymphadenectomy was performed as well.
For endometrial cancer and cervical cancer cases, mean
operative time was 243 and 296 minutes, mean estimated
blood loss was 190 mL and 270 mL, mean lymph node
count was 31.6 and 28.1, and mean hospital stay was 2
days and 3 days, respectively. The results, complications,
and adjuvant treatment of the study patients are summa-
rized in Table 2.
Three of the 17 patients (17.5%) with endometrial cancer
had node metastasis. The first had pelvic and paraaortic
involvement (clinical stage IA, clear cell carcinoma), and
the other 2 microscopic pelvic node metastases (both with
clinical stage IB grade 2 endometrioid cancer). All 3 re-
ceived adjuvant chemotherapy with carboplatin/pacli-
taxel and tailored external beam radiation. Four patients
with endometrioid endometrial cancer, stage IB grade 2
with negative nodes but risk factors such as positive lym-
phovascular involvement (n1) or lower uterine segment
involvement (n2) or both (n1), received adjuvant vag-
inal brachytherapy.
Nodal involvement was also present in 25% (2 of 8) of
cervical cancer patients. They both received adjuvant plat-
Table 1.
Patients Characteristics and Demographics
Total Laparoscopic Hysterectomy Total Radical Hysterectomy
Number (n) 17 8
Mean patient age (years) 61.6 (45–89) 39 (33–47)
BMI (kg/m
2) 32.3 (19.7–43.8) 24.1 (21.9–27.4)
Clinical Stage
Endometrial Cancer
IA 8 -
IB 7 -
IC 1 -
IIA 1 -
Endometrial Grade
G1 6 -
G2 9 -
G3 2 -
Endometrial Histology
Endometroid 16 -
Clear cell 1 -
Clinical Stage
Cervical Cancer:
IA2 - 4
IB1 - 2
IB2 - 1
IIA - 1
Cervical Histology:
Squamous - 5
Adenocarcinoma - 3
Type II/III Radical Ratio - 6/2
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large-volume stage IIA tumor and vaginal extension, ad-
ditional vaginal brachytherapy. Last, one patient with cer-
vical adenocarcinoma stage IB2 disease and negative
nodes received adjuvant pelvic radiation therapy due to
significant deep stromal invasion. The remaining 5 pa-
tients with cervical cancer had no additional risk factors
after surgery and are being observed by a standard sur-
veillance protocol.
The first patient suffered a left external iliac vein lacera-
tion. However, it was promptly repaired intraoperatively
with placement of vascular clips parallel to the vessel. In
the same patient, a blood transfusion was required with 2
units of packed red blood cells. The postoperative course
was uneventful. However, to minimize the risk of throm-
boembolic events, the patient was placed on a therapeutic
dose of unfractionated heparin, as per deep venous
thrombosis protocol. She was discharged on day 8 on oral
Coumadin. Two patients, one with endometrial cancer
and one with cervical cancer, developed asymptomatic
lymphocysts, with no further sequelae. The remaining 22
patients had no intraoperative, early or late postoperative
complications or infectious morbidity. An elderly patient
with clear cell endometrial cancer died of a noncancer-
related cause. At the time of this report, all patients remain
clinically disease-free.
At the conclusion of this study, a cost-analysis was imple-
mented by assessing the hospital’s accounting administra-
tion computer database. When almost only reusable in-
struments were utilized, the average standard hospital cost
for the laparoscopic procedures was decreased compared
with the cost of abdominal procedures. Abdominal pro-
cedures derived from cases performed by the authors
during the same study period in endometrial or cervical
cancer cases that either did not meet inclusion criteria for
the present study or were performed prior to the opening
Table 2.
Study Results, Complications and Postoperative Adjuvant Treatment
Total Laparoscopic Hysterectomy Total Laparoscopic Hysterectomy Total Radical Hysterectomy
Number (n) 17 8
Mean Operative Time (min 243 (120–300) 284 (210–480)
Mean Estimated Blood Loss (ml) 190 (50–250) 270 (250–300)
Mean Lymph Nodes Retrieved (n) 27.2 (10–39) 29.1 (14–42)
Mean Hospital Stay (days) 2 (1–3) 3 (1–8)
Conversion to Laparotomy (n) 0 0
Major Complications (%) 1/25 (4%)
Major and Minor Complications (%) 1/17 (6%) 2/8 (25%)
Total Complications (%) 3/25 (12%)
Intraoperative 0 1
Postoperative
Early (7 days) 0 0
Late (30 days) 1 1
Lymphocyst formation 1 1
Patients Upstaged Due to () Lymph Nodes (%) 17.5% (3/17) 25% (2/8)
Adjuvant Treatment (total n) 7 3
EBRT* plus Chemotherapy 3 -
Vaginal Brachytherapy 4 -
Pelvic EBRT - 1
Chemoradiation† - 1
Chemoradiation† plus Vaginal Brachytherapy - 1
*EBRT  external beam radiation therapy.
†Platinum based.
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Athens. However, when disposable instruments were ex-
tensively utilized (trocars, shears, electrocoagulation de-
vices, uterine manipulators, and others), the average ad-
justed hospital cost for the laparoscopic procedures was
significantly increased. Furthermore, the cost-analysis re-
vealed that in those cases where reusable instruments
were utilized along with the use of several disposable
instruments as deemed necessary, such as the laparo-
scopic endobag and laparoscopic vascular clip applicator,
the average calculated hospital cost of the laparoscopic
procedures was comparable to that of the abdominal
procedures, without affecting operative time, lymph node
yield, or safety (Table 3).
DISCUSSION
Laparoscopic staging for early stage endometrial and cer-
vical cancer had not been universally accepted until re-
cently. An increasing number of reports in the interna-
tional literature have assessed feasibility and safety data as
well as survival data, in both endometrial12,13 and cervical
cancers.14–16 To the best of our knowledge, this is the first
series of laparoscopic management of early stage endo-
metrial and cervical cancers in Greece.
The recent Gynecologic Oncology Group prospective
randomized study (LAP-2) of surgical staging in uterine
cancer, confirmed that the laparoscopic approach was
comparable to open surgery with equivalent surgical out-
comes and complications and that no difference exists in
long-term quality of life resulting from these techniques;
however, the laparoscopic approach was associated with
a decreased hospital length of stay, improved short-term
quality of life, and earlier return to baseline functioning.17
Similar results validating the role of laparoscopic manage-
ment of early cervical cancer are being published as well.
For example, a recent study from China with a 6-year
follow-up reported on 295 prospectively studied patients
with stage IA2-IIB cervical cancer. Operative time was
comparable to that of abdominal radical hysterectomy,
whereas estimated blood loss, hospital stay, and overall
complication rates were better in the laparoscopic group
compared with the laparotomy group. Follow-up at 72
months showed survival in 95.2%, 96.2%, and 84.5% of
patients with stage IA, IB, and IIA, respectively.18
Our goal in this study was to report on feasibility, safety,
and cost outcomes not previously described in our coun-
try. Surprisingly, the minority of European countries has
contributed to the existing pool of data, regarding feasi-
bility, safety, and cost of laparoscopic management of
endometrial and cervical cancers.
Operative time for both radical hysterectomy as well as
pelvic/paraaortic lymphadenectomy was longer for the
first 10 cases but has improved thereafter reflecting the
adjustment of our newly assembled surgical team. Lymph
nodes retrieved and hospital stays are comparable to
those of other published series.3–7 Our complication rate
in this series compares favorably to that of other published
series.15 Specifically, our overall major complication rate
reached an acceptable 4%. Nonetheless, such figures will
await confirmation from larger series.
All of our patients underwent routine pelvic and, in select
high-risk patients, additional paraaortic lymphadenec-
tomy. However, the role and extent of lymphadenectomy
in early endometrial cancer is still controversial and a
subject of ongoing debate in the gynecologic oncologic
Table 3.
Comparison of Calculated Costs (in Euros) Between Abdominal and Laparoscopic Approaches
Type of Procedure TAH-BSO, PLND
(/- PALND)*
TLH-BSO, PLND
(/- PALND)*
ARH-BSO PLND
(/- PALND)*
TLRH-BSO PLND
(/- PALND)*
Average Standard Cost† 4,000 3,000 4,500 4,000
Average Adjusted Hospital Cost‡ 4,750 4,900 5,000 5,500
Average Calculated Cost§ 4,250 4,400 4,750 5,000
*TAH  total abdominal hysterectomy; ARH  abdominal radical hysterectomy; TLH  total laparoscopic Hysterectomy; TLRH  total
laparoscopic radical hysterectomy; PLND  pelvic lymph node dissection; PALND  paraaortic lymph node dissection.
§In standard 4-bed patient room, assuming a 5–7 day stay in open and a 2–3 day stay in laparoscopic procedures utilizing mainly
reusable instruments.
‡Utilizing mainly disposable surgical instruments.
†Utilizing reusable and up to two on average disposable instruments in selected circumstances.
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mend systematic lymphadenectomy in early endometrial
cancer, even in patients with a priori low-risk fea-
tures.20–22 Others believe that lymphadenectomy, espe-
cially in low-risk endometrial cancer patients, may only
increase morbidity without an actual benefit for the pa-
tient.23 Adding to the existing controversy, surgical staging
requirements, such as sampling versus systemic lymphad-
enectomy or extent of lymphadenectomy, have not been
detailed by the 1998 FIGO cancer committee.24
The role of lymphadenectomy in early endometrial can-
cer, must await large well-designed randomized con-
trolled trials. Meanwhile our practice is to perform a sys-
temic lymphadenectomy in most endometrial cancer
patients. On this note, 2 of 6 patients with grade 2 lesions
and clinical stage IB had microscopic lymph node metas-
tases, and they both received adjuvant treatment. Similar
cases are commonly being managed by a total laparo-
scopic or abdominal hysterectomy and bilateral salpingo-
oophorectomy by many institutions.
Average standard costs for laparoscopic cases managed
using reusable-only instruments proved cheaper in our
institution compared with the abdominal ones, which may
be attributed mainly to the shorter hospital stay. However,
when disposable instruments were extensively used, the
adjusted costs tended to be higher. As the surgical team
gained more experience with laparoscopic staging, both
reusable and disposable—when deemed necessary—in-
struments were utilized bringing the calculated cost to
almost the same as that for the abdominal procedures.
The limitation of our study besides its size is also the lack
of a control arm both of which are common in reports of
this nature. Nonetheless, data have been prospectively
recorded and compare with those from similar published
series.3–9 Larger randomized trials from our country are
obviously required to validate our results. Our patient
database is being continuously populated by new cases
with the addition of robotic-assisted laparoscopy as well.
In the years to follow, we expect to also report on a larger
series along with survival outcomes.
Interestingly, a thorough PubMed/Medline literature
search reveals a relative paucity in related studies from
Eastern and Southeastern Europe compared with studies
from Scandinavian, Central, or Western European coun-
tries. However, the cost of such procedures as demon-
strated in our pilot study does not represent an actual
limiting factor in their application. The few published
studies from Eastern and Southeastern Europe probably
reflect an insufficient degree of training in minimally in-
vasive surgical techniques by gynecologic oncologists in
these countries.
CONCLUSION
The preliminary results from this pilot study support the
feasibility, safety, and cost effectiveness of laparoscopic
management of early stage endometrial and cervical can-
cer in our country. Such data may prove useful in stimu-
lating the gynecologic oncologic community in Greece
and other European countries, which may have been late
in adopting minimally invasive surgery in gynecologic
oncology, to engage in larger prospective studies.
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